The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management

被引:448
作者
Cooperberg, MR
Lubeck, DP
Meni, MV
Mehta, SS
Carroll, PR
机构
[1] Univ Calif San Francisco, Mt Zion Comprehens Canc Ctr, Dept Urol, Program Urol Oncol,Urol Outcomes Res Grp, San Francisco, CA 94115 USA
[2] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
关键词
D O I
10.1200/JCO.2004.10.062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. Early intervention for prostate cancer is associated with excellent long-term survival, but many affected men, especially those with low-risk disease characteristics, might not experience adverse impact to survival or quality of life were treatment deferred. We sought to characterize temporal trends in clinical presentation and primary disease management among patients with low-risk prostate cancer. Methods. Data were abstracted from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a disease registry of 8,685 men with various stages of prostate cancer. Included were 2,078 men who were diagnosed between 1989 and 2001 and had a serum prostate specific antigen less than or equal to 10 ng/mL, Gleason sum less than or equal to 6, and clinical T stage less than or equal to 2a. Trends in risk distribution, tumor characteristics, and primary treatment were evaluated. Results. The proportion of patients with low-risk tumor characteristics rose from 29.8% in 1989 to 1992, to 45.3% in 1999 to 2001 (P < .0001). There have been sharp increases in the use of brachytherapy and androgen deprivation monotherapy, from 3.1 % and 3.1 %, to 12.0% and 21.7%, respectively. Utilization rates for prostatectomy, external-beam radiotherapy, and observation have fallen accordingly, from 63.8%, 16.1%, and 13.8%, to 51.6%, 6.8%, and 7.9% P < .0001 for all except prostatectomy (P = .00191). Age and socioeconomic status were significantly associated with treatment selection, but overall, the treatment trends were echoed on subgroup analysis of patients 75 years or older. Conclusion. Low-risk features characterize a growing proportion of prostate cancer patients, and there have been significant shifts in the management of low-risk disease. Overtreatment may be a growing problem, especially among older patients. (C) 2004 by American Society of Clinical Oncology.
引用
收藏
页码:2141 / 2149
页数:9
相关论文
共 43 条
[1]   Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: A prospective and randomized study [J].
Akaza, H ;
Homma, Y ;
Okada, K ;
Yokoyama, M ;
Moriyama, N ;
Usami, M ;
Hirao, Y ;
Tsushima, T ;
Ohashi, Y ;
Aso, Y .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (03) :131-136
[2]   Do older men benefit from curative therapy of localized prostate cancer? [J].
Alibhai, SMH ;
Naglie, G ;
Nam, R ;
Trachtenberg, J ;
Krohn, MD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3318-3327
[3]  
ALIBHAI SMH, 2003, CANCER, V100, P1
[4]  
[Anonymous], 1997, Br J Urol, V79, P235
[5]  
[Anonymous], MAN CLIN LOC PROST C
[6]   Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial [J].
Aus, G ;
Abrahamsson, PA ;
Ahlgren, G ;
Hugosson, J ;
Lundberg, S ;
Schain, M ;
Schelin, S ;
Pedersen, K .
BJU INTERNATIONAL, 2002, 90 (06) :561-566
[7]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[8]   Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: A population based registry study [J].
Brasso, K ;
Friis, S ;
Juel, K ;
Jorgensen, T ;
Iversen, P .
JOURNAL OF UROLOGY, 1999, 161 (02) :524-528
[9]   Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results [J].
Carter, HB ;
Walsh, PC ;
Landis, P ;
Epstein, JI .
JOURNAL OF UROLOGY, 2002, 167 (03) :1231-1234
[10]   Critical evaluation of hormonal therapy for carcinoma of the prostate [J].
Chodak, GW ;
Keane, T ;
Klotz, L ;
Hormone Therapy Study Grp .
UROLOGY, 2002, 60 (02) :201-208